Oncoceutics Announces FDA Acceptance of Investigational New Drug Application for Phase I/II Trial of Novel Anti-Cancer Drug ONC201
Hummelstown, PA (March 4, 2014) – Oncoceutics, Inc., a biotechnology company focused on developing innovative oncology treatments addressing major unmet medical needs to advance cancer care, announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s Investigational New Drug (IND) application for the Phase I/II trial of ONC201, the lead drug compound